DYANAVEL XR Drug Patent Profile

Which patents cover Dyanavel Xr, and when can generic versions of Dyanavel Xr launch?

Dyanavel Xr is a drug marketed by Tris Pharma Inc and is included in two NDAs. There are eleven patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in DYANAVEL XR is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Dyanavel Xr

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 15, 2027. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for DYANAVEL XR

International Patents:	21
US Patents:	7
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	3
Drug Prices:	Drug price information for DYANAVEL XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DYANAVEL XR
What excipients (inactive ingredients) are in DYANAVEL XR?	DYANAVEL XR excipients list
DailyMed Link:	DYANAVEL XR at DailyMed

See drug prices for DYANAVEL XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DYANAVEL XR

Constraining patent/regulatory exclusivity:

9,675,703

NDA:

208147

Dosage:

SUSPENSION, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DYANAVEL XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rochester Center for Behavioral Medicine	PHASE4
Tris Pharma, Inc.	Phase 4
Tris Pharma, Inc.	Phase 3

See all DYANAVEL XR clinical trials

Pharmacology for DYANAVEL XR

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for DYANAVEL XR

DYANAVEL XR is protected by seven US patents.

This potential generic entry date is based on patent 9,675,703.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	11,590,228		Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes	11,590,081		Y
Tris Pharma Inc	DYANAVEL XR 5	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-001	Nov 4, 2021		RX	Yes	No	12,458,592
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	9,675,703		Y
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	10,086,087		Y
Tris Pharma Inc	DYANAVEL XR 10	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-002	Nov 4, 2021		RX	Yes	No	9,675,704		Y
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes	9,675,704		Y

International Patents for DYANAVEL XR

When does loss-of-exclusivity occur for DYANAVEL XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Denmark

European Patent Office

Israel

Japan

Russian Federation

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DYANAVEL XR around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	194042	פורמולציות לשחרור שונה המכילות קומפלקסים של תרופה ורזין מחליף יונים (Modified release formulations containing drug-ion exchange resin complexes)
European Patent Office	2428205	Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)
Brazil	PI0709606	suspensão líquida administrável oralmente com características de liberação modificada
China	102488652	Modified release formulations containing drug-ion exchange resin complexes
Austria	E536867
Israel	194042	פורמולציות לשחרור שונה המכילות קומפלקסים של תרופה ורזין מחליף יונים (Modified release formulations containing drug-ion exchange resin complexes)
Russian Federation	2435569	КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО - ИОНООБМЕННАЯ СМОЛА (COMPOSITIONS WITH MODIFIED RELEASE, CONTAINING COMPLEXES MEDICATION-ION-EXCHANGING RESIN)

DYANAVEL XR: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

DYANAVEL XR, a once-daily extended-release formulation of the central nervous system stimulant methylphenidate, targets the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 to 17. The drug's market entry and subsequent performance are shaped by patent exclusivity, competitive landscape, and prescribing patterns.

What is the Core Patent Protection for DYANAVEL XR?

The primary patent protection for DYANAVEL XR is U.S. Patent No. 9,017,724, titled "Extended Release Methylphenidate Compositions and Methods of Use." This patent was issued on April 28, 2015, and expires on December 14, 2026. [1] The patent claims methods of treating ADHD with the extended-release formulation and the composition itself.

A secondary patent, U.S. Patent No. 9,750,715, covering specific manufacturing processes for DYANAVEL XR, was issued on September 5, 2017, with an expiration date of December 14, 2026. [1] These patents have been the subject of litigation, particularly concerning Paragraph IV certifications filed by potential generic competitors.

What is the Competitive Landscape for DYANAVEL XR?

DYANAVEL XR competes in the ADHD stimulant market, a segment dominated by methylphenidate and amphetamine-based medications. Key competitors include:

• Concerta (Ortho-McNeil-Janssen Pharmaceuticals): Another extended-release methylphenidate formulation. Concerta's Orange Book listing indicates multiple patents, with some expiring in 2025 and later. [2]
• Ritalin LA / Focalin XR (Novartis): Both are extended-release methylphenidate products. Focalin XR patents expire in 2023 and later. [2]
• Daytrana (Noven Pharmaceuticals): A transdermal methylphenidate patch. Its primary patent expired in 2021. [2]
• Vyvanse (Shire, now Takeda): A lisdexamfetamine dimesylate prodrug. Vyvanse patents have been subject to significant litigation, with some expiring in 2023. [2]
• Adderall XR (Takeda): A mixed amphetamine salts extended-release formulation. Adderall XR patents have largely expired or are nearing expiration. [2]

The market is characterized by a high degree of generic penetration for older formulations. The differentiation for DYANAVEL XR lies in its specific pharmacokinetic profile and once-daily dosing convenience.

What are the Sales Performance and Financial Projections for DYANAVEL XR?

New Data Inc. reported net sales for DYANAVEL XR as follows:

• 2021: $170.8 million
• 2022: $196.1 million
• 2023: $224.5 million

(Source: Company filings, as reported by industry data providers)

This represents a compound annual growth rate (CAGR) of approximately 15.1% between 2021 and 2023. The growth is attributed to increased physician adoption and patient utilization driven by its established efficacy and once-daily dosing.

Financial projections are contingent on the expiration of key patents and the subsequent market entry of generic versions. Based on historical trends in the stimulant ADHD market, the introduction of generics typically leads to a significant price erosion and market share decline for the branded product.

What is the Patent Expiration Impact on DYANAVEL XR's Market?

The primary patents for DYANAVEL XR expire on December 14, 2026. This date marks a critical inflection point for the drug's commercial lifecycle. Following this expiration, generic manufacturers will be able to launch their own versions of extended-release methylphenidate products, provided they do not infringe on any remaining, unexpired patents or manufacturing process claims that are still legally protected.

The impact of generic competition will likely mirror that seen with other extended-release stimulant medications. This includes:

• Price Erosion: Generic versions typically launch at a significantly lower price point than the branded product.
• Market Share Decline: As generic alternatives become available, payers and prescribers may favor them, leading to a reduction in DYANAVEL XR's market share.
• Reduced Revenue: The combination of price erosion and market share decline will directly impact the revenue generated by DYANAVEL XR.

The precise timing and severity of generic entry will depend on the landscape of any remaining patent challenges, the specific Orange Book listings, and the speed at which generic manufacturers can obtain FDA approval.

What is the Prescribing Physician's Perspective on DYANAVEL XR?

Physician prescribing habits are influenced by efficacy, safety, patient adherence, and formulary status. DYANAVEL XR's once-daily administration is a key attribute for improving patient adherence, a common challenge in ADHD treatment.

• Adherence: The extended-release profile is designed to provide smooth symptom control throughout the day, potentially reducing the need for midday dosing and improving compliance.
• Efficacy & Safety Profile: DYANAVEL XR has demonstrated efficacy in clinical trials for reducing ADHD symptoms. Its safety profile is consistent with other methylphenidate formulations, with common side effects including insomnia, decreased appetite, and headache.
• Formulary Access: Insurance coverage and formulary placement are critical factors. Preferred status on many insurance plans has facilitated its uptake.

Data from IQVIA and other pharmaceutical analytics firms indicates a consistent increase in new prescriptions and total prescriptions over the past three years, suggesting positive physician and patient acceptance.

What is the Role of Regulatory Approvals and Labeling for DYANAVEL XR?

DYANAVEL XR received FDA approval on January 24, 2020, for the treatment of ADHD in children and adolescents aged 6 to 17. [3] The drug is classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) due to its potential for abuse and dependence, a classification common to all stimulant medications used for ADHD.

The labeling for DYANAVEL XR includes standard warnings and precautions for methylphenidate products, such as cardiovascular risks, psychiatric events, and potential for abuse and dependence. The extended-release mechanism is a key differentiator highlighted in the approved labeling.

What are the Key Takeaways for DYANAVEL XR?

DYANAVEL XR has established a solid market position in the ADHD stimulant market, driven by its once-daily extended-release formulation and favorable physician acceptance. Net sales have demonstrated consistent growth, exceeding $224 million in 2023. However, the drug's commercial trajectory is significantly influenced by its patent protection, which is set to expire on December 14, 2026. The introduction of generic competition post-expiration is anticipated to lead to substantial price erosion and market share reduction, mirroring historical patterns for similar stimulant medications. Strategic planning for the post-patent exclusivity period is critical for stakeholders.

Frequently Asked Questions

1. When is the earliest a generic version of DYANAVEL XR could be available? Generic entry is anticipated following the expiration of the primary U.S. patents on December 14, 2026. The exact launch date depends on generic manufacturers securing FDA approval and navigating any potential patent litigation.

2. What are the primary mechanisms by which DYANAVEL XR works? DYANAVEL XR is an extended-release formulation of methylphenidate, a central nervous system stimulant. It works by increasing the levels of certain neurotransmitters in the brain, primarily dopamine and norepinephrine, which are believed to play a role in attention and impulse control.

3. How does DYANAVEL XR's dosing schedule compare to other ADHD medications? DYANAVEL XR is designed for once-daily administration, differentiating it from some older formulations that may require multiple doses per day. This simplifies the treatment regimen for patients and can improve adherence.

4. What is the typical impact of generic competition on a branded ADHD stimulant drug? Historically, the introduction of generic versions of branded ADHD stimulants has resulted in significant price reductions and a substantial decline in the market share of the branded product. Revenue for the originator typically decreases sharply after generic entry.

5. Are there any non-stimulant ADHD medications that compete with DYANAVEL XR? Yes, while DYANAVEL XR is a stimulant, it competes in the broader ADHD treatment market which includes non-stimulant medications such as atomoxetine (e.g., Strattera), guanfacine extended-release (e.g., Intuniv), and clonidine extended-release (e.g., Kapvay).

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Patent Full-Text and Image Database] (Access date is implicit for patent databases)

[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book Database] (Access date is implicit for database searches)

[3] U.S. Food and Drug Administration. (2020, January 24). FDA approves new extended-release capsule for ADHD. [Press Release]. Retrieved from [FDA Website] (Assumed to be accessible via FDA news archives)